On February 9, 2023 Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, reported that it will release its fourth quarter and second half 2022 results on Thursday, 16 February 2023 at 8am CEST (Press release, Lytix Biopharma, FEB 9, 2023, View Source [SID1234627020]). The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 2:30pm CEST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We encourage you to send us questions in advance, to be addressed during the Q&A session. Please send your email to [email protected].

The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here: View Source

A recording of the presentation will be made available on View Source after the presentation